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COMMENTARIES
MEDICINE AND LAW

President’s Emergency Plan for AIDS Relief
Health Development at the Crossroads
Lawrence O. Gostin, JD

T

HE UNITED STATES GLOBAL LEADERSHIP AGAINST
HIV/AIDS, Tuberculosis, and Malaria Act of 2003,
which funded the President’s Emergency Plan for
AIDS Relief (PEPFAR), was the largest commitment by any nation to combat a single disease in human
history, authorizing up to $15 billion over 5 years. On July
30, 2008, President Bush signed into law the historic reauthorization of PEPFAR, dramatically increasing the financial commitment by authorizing up to $48 billion over 5
years, including $5 billion for malaria and $4 billion for
tuberculosis. During the signing ceremony, the president
said, “There is no way to quantify PEPFAR’s greatest
achievement: the spread of hope. . . . And spreading hope is
in our moral interests—because we believe that to whom
much is given, much is required.”1 PEPFAR’s global targets
are inspiring: treat 3 million people; prevent 12 million
new human immunodeficiency virus (HIV) infections, and
care for 12 million people, including 5 million orphans and
vulnerable children.
PEPFAR has been mired in controversy. To some, it
exemplifies the United States’ extraordinary compassion
and generosity; to others, it symbolizes the politicization of
public health and unilateral approach to international
health. The truth lies somewhere in between. The latest
data on global health assistance predates the reauthorization, but includes the original PEPFAR. In 2007, the
United States donated $21.8 billion in official development
assistance, more than any other country, and the United
States is the only country projected to meet the 2005
Group of 8 (G8) Gleneagles commitment to double aid to
sub-Saharan Africa by 2010. Yet, in 2007, the United States
devoted only 0.16% of its gross national income to official
development assistance, placing it last among G8 countries, with nearly 70% going to AIDS.2 The United States is
tied for last on aid effectiveness using a set of 10 critical
indicators.3
US health assistance to the developing world stands
at a crossroad. As PEPFAR is scaled up, will it provide
opportunities to fulfill basic human needs or will its
limited focus pull resources from sustainable, capacity-building support in line with poor country priorities?4
2046 JAMA, November 5, 2008—Vol 300, No. 17 (Reprinted)

Spending Directives: Prevention, Treatment,
and Care
PEPFAR is prescriptive on how the funds can be spent, irrespective of country priorities. The reauthorization requires half
of bilateral aid spent on treatment and care, with at least 10%
spent on orphans and vulnerable children. The focus on antiretroviral treatment is extraordinary, reflecting an ethic of
universal access to lifesaving medicines for rich and poor alike.5
When PEPFAR was launched in 2003, only 50 000 Africans
(⬍2% of the 4.4 million in need) received antiretroviral treatment, but by March 31, 2008, PEPFAR supported antiretroviral treatment for approximately 1.73 million people, mostly
in focus countries in sub-Saharan Africa.4,6
Treatment is a humanitarian triumph, rescuing individuals and their families from a dire fate, but from a population perspective it does little to stem the tide of the pandemic. For every individual to receive treatment, 2 to 3 others
become newly infected. Although prevention and treatment are intertwined and it is unfair to pit one against the
other, there are nevertheless inherent trade-offs in the use
of scarce health resources. Treatment is, at best, a stop-gap
measure that requires enormous resources because of the
life-long need of millions of individuals. The current costs
are approximately $2 billion annually, an amount that could
increase to $12 billion by 2016, more than half of US official development assistance.7 The cost, moreover, could increase considerably with the increase in drug-resistant forms
of HIV, requiring expensive second-line medications.8 Additionally, patient retention in treatment programs has often been relatively poor in sub-Saharan Africa9; if PEPFAR
treatment dollars are to be spent effectively, retention in care
should become just as important as expanded enrollment.
The United States’ impressive leadership in global AIDS,
therefore, would be more effective if PEPFAR focused on
comprehensive behavioral strategies, condoms, male circumcision, and structural approaches such as social, economic, political, and environmental factors that have an evidence base for preventing new infections.10 It is for these
reasons that the Institute of Medicine recommended eliminating PEPFAR’s spending directives,11 and the US GovernAuthor Affiliation: O’Neill Institute for National and Global Health Law, Georgetown University, Washington, DC.
Corresponding Author: Lawrence O. Gostin, JD, Georgetown University Law Center, 600 New Jersey Law Center, NW, Washington, DC 20001 (gostin@law
.georgetown.edu).
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ment Accountability Office proposed a more countryfocused approach.12
More broadly, reliance on vertical or disease-specific programs is less effective than building health system capacity
and human resources, as well as serving priority health needs
as determined by the host country. Although it is primarily
a single-disease program, PEPFAR deserves credit for
strengthening the health workforce, promoting local clinics, supporting nutrition, and increasing integration with
malaria and tuberculosis services. Nevertheless, focusing on
“basic survival needs” such as clean water, sanitation, pest
abatement, and essential medicines for a broad range of health
conditions could save even more lives by addressing the major determinants of health.13
Politics of AIDS
AIDS policy has been embroiled in politics since the beginning of the HIV epidemic. The ideological aspects inherent in
PEPFAR tarnish its reputation, but it is important to stress that
without political compromise, AIDS funding on such an unprecedented scale would not have been politically possible.
Abstinence and Faithfulness. The PEPFAR reauthorization removes the 2003 requirement that 33% of prevention
funds be spent on abstinence-until-marriage programs but still
requires host countries to meaningfully and equitably support “activities promoting abstinence, delay of sexual début,
monogamy, fidelity, and partner reduction.”14 The administration must report to Congress if a host country spends less
than half its prevention funds for these purposes. The “ABC”
(abstinence, be faithful, and use condoms) approach can be
effective, but PEPFAR prevention dollars may go to organizations that withhold information about condoms or other contraception services, thus restricting access to lifesaving information. Even worse, PEPFAR’s 2008 “conscience clause” allows
organizations with a moral or religious objection to opt out
of providing services to which they may object, and that could
pave the way for PEPFAR funding recipients to refuse care
based on their disapproval of a patient’s behavior or sexual
orientation. The “soft” prescription to focus half of prevention funds on abstinence and faithfulness programs can distort priorities but will not have the same binding force as the
abstinence-only mandate in 2003.
Family Planning: Gender and Youth. Family planning
programs may receive funding for HIV services only, irrespective of their compliance with the Mexico City policy,
which means that groups providing or counseling women
about legal abortions are eligible for PEPFAR funding. The
PEPFAR reauthorization admirably requires global HIV/
AIDS prevention strategies to address the vulnerability of
women and youth, with a target of 80% coverage for preventing mother-to-child transmission. Yet, PEPFAR misses
an opportunity to better serve women and girls by strengthening critical linkages between family planning, reproductive health services, and HIV prevention—helping vulnerable groups with unmet needs.
©2008 American Medical Association. All rights reserved.

Prostitution and Sex Trafficking. PEPFAR proscribes
funding any group without a policy “explicitly opposing prostitution and sex trafficking,” thus requiring organizations
to pledge opposition to marginalized individuals, driving
them underground. A federal court of appeals upheld the
same provision in the original PEPFAR, reasoning that “the
government can—and often must—discriminate on the basis of viewpoint,”15 even though the organization believes
that opposition to commercial sex work stigmatizes and alienates those most vulnerable to HIV/AIDS.
Immigration and Travel
In 1987, a time when HIV was poorly understood, the Secretary of the US Department of Health and Human Services, in response to congressional direction in the Helms
Amendment, added HIV infection to the list of communicable diseases of public health importance, which restricted travel or immigration to the United States, whether
for vacation, employment, or conference attendance. Although the Bureau of Citizenship and Immigration Services can grant a waiver, the conditions are restrictive.
By the early 1990s, recognizing the absence of a public health
justification, the Department of Health and Human Services
reversed its position, but the Immigration and Nationality Act
of 1993 codified the ban; HIV is the only disease specifically
named for exclusion from the United States. The ban has been
widely condemned as arbitrary and discriminatory and led to
the International AIDS Society refusing to hold its annual conference in the United States. The PEPFAR reauthorization ends
the statutory exclusion of travelers and immigrants to the
United States, thus demonstrating respect for the human rights
and dignity of the person and restoring its reputation in the
international AIDS community.
PEPFAR: A Turning Point for Global Health
AIDS advocates have been highly conflicted about PEPFAR,
recognizing its unprecedented generosity but torn by its moralizing and constraining spending mandates. It is tempting to
focus on PEPFAR’s undeniable deficiencies—prioritizing treatment over prevention, stressing abstinence and faithfulness,
forcing clinicians to condemn sex workers against their beliefs, and not doing enough to empower women and youth.
But beyond these deficiencies, PEPFAR has transformed lives
and instilled a sense of hope in poor African communities ravaged by AIDS that is heartening and palpable on the ground.
PEPFAR represents a milestone in development assistance, but the United States and its rich global partners face
a critical choice. PEPFAR can remain a vertical program of
exceptional value that will cease when political will subsides. Alternatively, rich countries can build on PEPFAR by
making a historic commitment to international development assistance for health that is scalable and sustainable
and that attacks the root causes of poverty, inequality, and
early death. By ensuring the capacity of poor countries to
take care of their own with decent living conditions, hy(Reprinted) JAMA, November 5, 2008—Vol 300, No. 17
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giene, and health systems, the international community can
make an enduring, truly historical improvement in the lives
of the world’s least healthy people.
Financial Disclosures: None reported.
Additional Contributions: John Kraemer, Fellow of the O’Neill Institute, assisted
with research, editing, and writing as part of his fellowship.
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US Health Aid Beyond PEPFAR
The Mother & Child Campaign
Colleen C. Denny, BS
Ezekiel J. Emanuel, MD, PhD

O

NE OF THE GEORGE W. BUSH ADMINISTRATION’S
biggest successes has been the President’s Emergency Plan for AIDS Relief (PEPFAR).1 Even the
president’s critics acknowledge the important
benefits PEPFAR has produced, both for those countries most
seriously affected by human immunodeficiency virus (HIV)/
AIDS and for the United States’ moral legitimacy and diplomatic reputation. It was accordingly unsurprising that the
president used his final State of the Union address to call
for a doubling of PEPFAR’s funds. Congress recently went
even further, appropriating nearly $50 billion for the program’s renewal.1
Yet doubling or tripling PEPFAR’s funding is not the
best use of international health funding. In focusing so
heavily on HIV/AIDS treatments, the United States misses
huge opportunities. By extending funds to simple but
more deadly diseases, such as respiratory and diarrheal
illnesses, the US government could save more lives—
especially young lives—at substantially lower cost. Rather
than inflating PEPFAR funding, the newly pledged billions
could launch a new proposal program called the Mother &
Child Campaign.
2048 JAMA, November 5, 2008—Vol 300, No. 17 (Reprinted)

PEPFAR’s Purview
In 2003, Congress appropriated PEPFAR $15 billion over
5 years to combat HIV/AIDS in developing regions. By September 2007, the program had prevented mother-to-child
transmission for 10 million pregnancies, supported outreach activities aimed at preventing transmission to 61.5 million people, and provided antiretroviral treatment (ART) to
1.45 million individuals.1 United States citizens generally
strongly support PEPFAR, partly because of the devastating effects of HIV/AIDS—the disease claims 1.9 million lives
annually in lower-income countries—but also because HIV/
AIDS is one of the few major health problems the United
States shares with the developing world, and because it primarily affects adults, who have greater economic and political power.2
Yet despite being “the largest commitment ever by a
single nation toward an international health initiative,”1
PEPFAR fails to address many of the developing world’s
most serious health threats. In lower-income countries,
mundane but deadly diseases cause more harm than HIV/
AIDS. Respiratory infections alone claim 2.86 million lives
Author Affiliations: Department of Bioethics, the Clinical Center, National Institutes of Health, Bethesda, Maryland.
Corresponding Author: Ezekiel J. Emanuel, MD, PhD, Department of Bioethics,
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